Logotype for SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group (SLS) investor relations material

SELLAS Life Sciences Group Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for SELLAS Life Sciences Group Inc
Q2 2025 earnings summary12 Aug, 2025

Executive summary

  • SLS009 showed positive Phase 2 results in relapsed/refractory AML, meeting all primary endpoints with a 44% response rate in AML-MRC and median overall survival of 8.9 months, nearly tripling historical benchmarks; FDA guidance received to advance to first-line AML trial by Q1 2026.

  • REGAL Phase 3 trial for GPS in AML is ongoing, with interim analysis completed and a positive IDMC recommendation to continue; final analysis expected by year-end 2025.

  • Expanded Scientific Advisory Board with oncology experts and presented promising preclinical data for SLS009 in ASXL1-mutated colorectal cancer and T-PLL.

  • No product sales revenue; licensing revenue only from 3D Medicines Agreement, with ongoing arbitration over milestone payments.

  • Inclusion in the Russell 3000 and Russell 2000 indexes, enhancing market visibility.

Financial highlights

  • Net loss for Q2 2025 was $6.6 million ($0.07 per share), improved from $7.5 million ($0.13 per share) in Q2 2024; net loss for the first half of 2025 was $12.4 million ($0.13 per share), down from $17.0 million ($0.33 per share) prior year.

  • R&D expenses for Q2 2025 were $3.9 million, down from $5.2 million in Q2 2024, mainly due to completion of REGAL study enrollment; first half 2025 R&D expenses were $7.1 million, down from $10.3 million year-over-year.

  • G&A expenses for Q2 2025 were $3.0 million, up from $2.4 million in Q2 2024; first half 2025 G&A expenses were $5.9 million, down from $7.0 million year-over-year.

  • Cash and cash equivalents were $25.3 million as of June 30, 2025, up from $13.9 million at year-end 2024, with an additional $4.0 million received in July 2025 from warrant exercises.

  • No revenue recognized in the quarter; $191.5 million in potential future milestones under the 3D Medicines Agreement remain.

Outlook and guidance

  • Cash and cash equivalents are not sufficient to fund planned operations for the next twelve months; substantial doubt exists about ability to continue as a going concern.

  • Additional financing will be required to support ongoing development and operations; management is evaluating funding strategies.

  • Research and development expenses expected to increase as GPS approaches potential BLA filing and SLS009 advances to first-line AML trial.

  • Final analysis of the Phase 3 REGAL trial of GPS in AML expected by year-end 2025.

  • Enrollment for the first-line SLS009 AML trial anticipated to begin by Q1 2026.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next SELLAS Life Sciences Group earnings date

Logotype for SELLAS Life Sciences Group Inc
Status Update29 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next SELLAS Life Sciences Group earnings date

Logotype for SELLAS Life Sciences Group Inc
Status Update29 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

SELLAS Life Sciences Group Inc. is a biopharmaceutical company focused on developing immunotherapies for cancer. The company specializes in targeted peptide-based therapies designed to stimulate the immune system against various tumor types. Its research and development efforts aim to advance novel cancer treatments through clinical trials and regulatory approvals. The company is headquartered in Montvale, New Jersey, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage